Literature DB >> 28539785

Giant cell arteritis: a review.

Pravin Patil1, Niral Karia2, Shaifali Jain3, Bhaskar Dasgupta1.   

Abstract

Giant cell arteritis is the most common vasculitis in Caucasians. Acute visual loss in one or both eyes is by far the most feared and irreversible complication of giant cell arteritis. This article reviews recent guidelines on early recognition of systemic, cranial, and ophthalmic manifestations, and current management and diagnostic strategies and advances in imaging. We share our experience of the fast track pathway and imaging in associated disorders, such as large-vessel vasculitis.

Entities:  

Keywords:  diagnosis; giant cell arteritis; polymyalgia rheumatica; treatment

Year:  2013        PMID: 28539785      PMCID: PMC5432116          DOI: 10.2147/EB.S21825

Source DB:  PubMed          Journal:  Eye Brain        ISSN: 1179-2744


  76 in total

1.  BSR and BHPR guidelines for the management of giant cell arteritis.

Authors:  Bhaskar Dasgupta; Frances A Borg; Nada Hassan; Leslie Alexander; Kevin Barraclough; Brian Bourke; Joan Fulcher; Jane Hollywood; Andrew Hutchings; Pat James; Valerie Kyle; Jennifer Nott; Michael Power; Ash Samanta
Journal:  Rheumatology (Oxford)       Date:  2010-04-05       Impact factor: 7.580

2.  Comment on: Risk factors for severe cranial ischaemic events in an Italian population-based cohort of patients with giant cell arteritis.

Authors:  Olivier Steichen
Journal:  Rheumatology (Oxford)       Date:  2009-07-09       Impact factor: 7.580

3.  Ischaemic manifestations in giant cell arteritis are associated with area level socio-economic deprivation, but not cardiovascular risk factors.

Authors:  Sarah L Mackie; Bhaskar Dasgupta; Lesley Hordon; Andrew Gough; Michael Green; Jane Hollywood; Shouma Dutta; Victoria Bejarano; Stephen Jarrett; Ann W Morgan; Colin T Pease
Journal:  Rheumatology (Oxford)       Date:  2011-08-22       Impact factor: 7.580

4.  Interleukin 6 blockade as steroid-sparing treatment for 2 patients with giant cell arteritis.

Authors:  Savino Sciascia; Daniela Rossi; Dario Roccatello
Journal:  J Rheumatol       Date:  2011-09       Impact factor: 4.666

5.  Influence of traditional risk factors of atherosclerosis in the development of severe ischemic complications in giant cell arteritis.

Authors:  Miguel A Gonzalez-Gay; Angela Piñeiro; Adriana Gomez-Gigirey; Carlos Garcia-Porrua; Robustiano Pego-Reigosa; Trinidad Dierssen-Sotos; Javier Llorca
Journal:  Medicine (Baltimore)       Date:  2004-11       Impact factor: 1.889

6.  Giant cell arteritis and polymyalgia rheumatica in a region of Finland: an epidemiologic, clinical and pathologic study, 1984-1988.

Authors:  P Franzén; S Sutinen; J von Knorring
Journal:  J Rheumatol       Date:  1992-02       Impact factor: 4.666

7.  Antiplatelet and anticoagulant therapy in patients with giant cell arteritis.

Authors:  Michael S Lee; Scott D Smith; Anat Galor; Gary S Hoffman
Journal:  Arthritis Rheum       Date:  2006-10

Review 8.  Giant cell arteritis: an updated review.

Authors:  Aki Kawasaki; Valerie Purvin
Journal:  Acta Ophthalmol       Date:  2008-10-07       Impact factor: 3.761

9.  Polymyalgia rheumatica and giant cell arteritis: a 5-year epidemiologic and clinical study in Reggio Emilia, Italy.

Authors:  C Salvarani; P L Macchioni; P L Tartoni; F Rossi; R Baricchi; C Castri; F Chiaravalloti; I Portioli
Journal:  Clin Exp Rheumatol       Date:  1987 Jul-Sep       Impact factor: 4.473

10.  Repetitive 18F-fluorodeoxyglucose positron emission tomography in giant cell arteritis: a prospective study of 35 patients.

Authors:  Daniël Blockmans; Liesbet de Ceuninck; Steven Vanderschueren; Daniël Knockaert; Luc Mortelmans; Herman Bobbaers
Journal:  Arthritis Rheum       Date:  2006-02-15
View more
  9 in total

Review 1.  Imaging in Giant Cell Arteritis.

Authors:  Asad Khan; Bhaskar Dasgupta
Journal:  Curr Rheumatol Rep       Date:  2015-08       Impact factor: 4.592

2.  Population-based Rate and Patterns of Diplopia in Giant Cell Arteritis.

Authors:  Clara M Castillejo Becerra; Cynthia S Crowson; Matthew J Koster; Kenneth J Warrington; M Tariq Bhatti; John J Chen
Journal:  Neuroophthalmology       Date:  2021-08-20

3.  Diagnostic positron emission tomography-computed tomography in clinically elusive giant cell arteritis.

Authors:  Ryian Mohamed; Deyl Djama; Tariq Ayoub
Journal:  Indian J Ophthalmol       Date:  2018-05       Impact factor: 1.848

4.  Ultrasound versus temporal artery biopsy in patients with Giant cell arteritis: a prospective cohort study.

Authors:  Quan Zou; Sumei Ma; Xinghu Zhou
Journal:  BMC Med Imaging       Date:  2019-06-06       Impact factor: 1.930

Review 5.  Giant Cell Arteritis: A Case-Based Narrative Review of the Literature.

Authors:  Davis C Thomas; Prisly Thomas; Deep P Pillai; Dahlia Joseph; Upasana Lingaiah; Blessy C Mathai; Anjali Ravi; Surabhi Chhabra; Priyanka Kodaganallur Pitchumani
Journal:  Curr Pain Headache Rep       Date:  2022-09-03

6.  Novel ultrasonographic Halo Score for giant cell arteritis: assessment of diagnostic accuracy and association with ocular ischaemia.

Authors:  Kornelis S M van der Geest; Frances Borg; Abdul Kayani; Davy Paap; Prisca Gondo; Wolfgang Schmidt; Raashid Ahmed Luqmani; Bhaskar Dasgupta
Journal:  Ann Rheum Dis       Date:  2020-01-03       Impact factor: 27.973

7.  The Impact of Temporal Artery Biopsy at a UK Tertiary Plastic Surgery Unit.

Authors:  Bryan J W Chew; Ankur Khajuria; Javier Ibanez
Journal:  Plast Reconstr Surg Glob Open       Date:  2019-11-27

Review 8.  Therapeutic options for patients with rare rheumatic diseases: a systematic review and meta-analysis.

Authors:  Tim T A Bender; Judith Leyens; Julia Sellin; Dmitrij Kravchenko; Rupert Conrad; Martin Mücke; Matthias F Seidel
Journal:  Orphanet J Rare Dis       Date:  2020-10-31       Impact factor: 4.123

9.  Tocilizumab-associated posterior reversible encephalopathy syndrome in giant-cell arteritis - case report.

Authors:  Michaela Butryn; Sabine Mewes; Eugen Feist; Oliver Beuing; Christian Müller; Jens Neumann
Journal:  BMC Neurol       Date:  2021-06-22       Impact factor: 2.474

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.